Monopar Therapeutics (NASDAQ:MNPR) Trading Down 3.9% – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price fell 3.9% on Friday . The company traded as low as $106.50 and last traded at $106.55. Approximately 64,031 shares traded hands during trading, a decline of 71% from the average session volume of 220,969 shares. The stock had previously closed at $110.88.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MNPR. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. HC Wainwright boosted their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

Monopar Therapeutics Stock Performance

The stock has a market capitalization of $722.80 million, a P/E ratio of -49.64 and a beta of 1.47. The stock has a 50-day moving average price of $101.68 and a two-hundred day moving average price of $73.21.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities analysts anticipate that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics in the 1st quarter worth $673,000. Jane Street Group LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter worth about $377,000. Geode Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after purchasing an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Monopar Therapeutics during the second quarter valued at about $209,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.